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Abstract: The development of selective agonists of δ-opioid receptor as well as the model of 
interaction of ligands with this receptor is the subjects of increased interest. In the absence 
of crystal structures of opioid receptors, 3D homology models with different templates have 
been reported in the literature. The problem is that these models are not available for 
widespread use. The aims of our study are: (1) to choose within recently published 
crystallographic structures templates for homology modeling of the human δ-opioid receptor 
(DOR); (2) to evaluate the models with different computational tools; and (3) to precise the 
most reliable model basing on correlation between docking data and in vitro bioassay 
results. 
 
The enkephalin analogues, as ligands used in this study, were previously synthesized by our 
group and their biological activity was evaluated. Several models of DOR were generated 
using different templates. All these models were evaluated by PROCHECK and MolProbity 
and relationship between docking data and in vitro results was determined. The best 
correlations received for the tested models of DOR were found between efficacy (erel) of the 
compounds, calculated from in vitro experiments and Fitness scoring function from docking 
studies. 
 
New model of DOR was generated and evaluated by different approaches. This model has 
good GA341 value (0.99) from MODELLER, good values from PROCHECK (92.6% of most 
favored regions) and MolProbity (99.5% of favored regions). Scoring function correlates 
(Pearson r = -0.7368, p-value = 0.0097) with erel of a series of enkephalin analogues, 
calculated from in vitro experiments. So, this investigation allows suggesting a reliable 
model of DOR. 
 
Newly generated model of DOR receptor could be used further for in silico experiments and 
it will give possibility for faster and more correct design of selective and effective ligands for 
δ-opioid receptor. 
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Introduction 
The opioid receptors are very important class of receptors that attract the attention of huge 
number of scientists. Development of the effective and selective ligands to each opioid 
receptor is a time consuming process, which involves knowledge and skills of different 
researchers: chemists, biologists, medics, pharmacologists, etc. Large number of compounds 
with opioid action were synthesized, characterized and biologically tested, but just some of 
them are with desired efficacy and selectivity to the respective opioid receptor.  
On the other hand the isolation and crystallization of opioid receptors is very heavy task, due 
to their location. All of them are trans-membrane proteins and the isolation causes destruction 
of their tertiary structure. So, these are the reasons to search for different approaches for 
solving this problem. Many experiments, concerning mutation of the binding site of opioid 
receptors, were done in order to determine the key amino acid positions in the receptor, which 
are responsible for their action. Different theoretical models were proposed, but they are not 
available for the investigators in that field, because theoretical models have not been 
published in data base.  
The aims of our study are: (1) to choose within recently published crystallographic structures 
templates for homology modeling of the human δ-opioid receptor (DOR); (2) to evaluate the 
models with different computational tools; and (3) to precise the most reliable model basing 
on correlation between docking data and in vitro bioassay results. 
 
Materials and methods 
Computational tools 
In order to perform computational studies the different software is used in the present work. 
The protein sequence of δ-opioid receptor was obtained from UNIPROT. Homology 
modeling studies were carried out using Chimera, that provides a graphical interface to 
running the program Modeller via a Web service, hosted by the UCSF RBVI [1]. Ligand 
preparation was done with MOE (Molecular Operating Environment) [2]. Docking studies 
were performed by using GOLD 5.1 (Genetic Optimization for Ligand Docking) [3], run on 
Scientific LINUX 5.5 operating system. Molegro Molecular Viewer [4] was used for 
generating figures. 
 
Sequence alignment 
The protein sequence for the DOR was obtained from the Swiss Prot database (accession 
number P41143). For homology models based on multiple templates, the template search was 
done with sequence search option of RCSB [5]. Better hits were proved to be with the 
following recent deposition of crystallographic structures: of turkey β-1 adrenergic receptor 
with stabilizing mutations and bound partial agonist dobutamine (PDB id: 2Y00), structure of 
the PilM-PilN inner membrane type IV pilus biogenesis complex from Thermus thermophilus 
(PDB id: 2YCX), crystal structure of human adenosine A2A receptor with an allosteric 
inverse-agonist antibody at 2.7 Å resolution (PDB id: 3VG9), solution conformation of 
substance P in water complexed with NK1R (PDB id: 2KS9), and crystal structure of the 
human beta-2 adrenoceptor (PDB id:2r4s). The alignment of DOR to a particular template 
(bovine or bacteriorhodopsin) resulted in some gaps. Hence, to retrieve the best possible 
alignment for this target and reduce the gaps as much as possible, MSA was carried out with 
CLUSTALW using the templates found as top hits as a result of BLAST search. In 
CLUSTALW, the default alignment matrix GONNET 250 was used. The default parameter 
for gap open penalty was 10.2, gap extension penalty was 0.2 and gap distance was 4. MSA 
with 2y00, 2ycx, 2r4s, 3vg9, 3ks9, and 2a4m for DOR, is presented in Fig. 1.   INT. J. BIOAUTOMATION, 2013, 17(1), 5-16 
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3D model generation and validation 
Based on the MSA derived with CLUSTALW, 3D models of DOR were built using 
MODELLER of Chimera package with default parameters. The model with higher GA341 
score (more than 95%) was chosen as a model for further evaluations. Validation of the 
structural quality of the generated models was done using PROCHECK [6] and   
MolProbity [7]. 
 
Docking of ligands 
Eleven ligands, investigated for their potency, selectivity and efficacy to DOR with in vitro 
bioassay in our previous study [8], were selected for docking studies. Their primary structure, 
including that of selective ligand DPDPE and endogenous enkephalins, is presented in   
Table 1. 
 
Table 1. Enkephalin analogues used as ligands in our study 
 Ligand  Primary  structure 
1 
DPDPE  Tyr-D-Pen-Gly-Phe-D-Pen  
2 [Leu
5]-enk Tyr-Gly-Gly-Phe-Leu 
3 [Met
5]-enk Tyr-Gly-Gly-Phe-Met 
4 [Cys(Bzl)
2, Leu
5]-enk Tyr-Cys(Bzl)-Gly-Phe-Leu 
5 [Cys(Bzl)
2, Met
5]-enk Tyr-Cys(Bzl)-Gly-Phe-Met 
6 [Cys(O2NH2)
2, Leu
5]-enk Tyr-Cys(O2NH2)-Gly-Phe-Leu 
7 [Cys(O2NH2)
2, Met
5]-enk Tyr-Cys(O2NH2)-Gly-Phe-Met 
8 [DCys(O2NH2)
2, Leu
5]-enk Tyr-D-Cys(O2NH2)-Gly-Phe-Leu 
9 [DCys(O2NH2)
2, Met
5]-enk Tyr-D-Cys(O2NH2)-Gly-Phe-Met 
10 [HCys(O2NH2)
2, Leu
5]-enk Tyr-HCys(O2NH2)-Gly-Phe-Leu 
11 [HCys(O2NH2)
2, Met
5]-enk Tyr-HCys(O2NH2)-Gly-Phe-Met 
 
3D structures of the ligands were modeled in MOE. Ligands were protonated at physiological 
pH 7.4.  
 
Docking was carried out with GOLD 5.1 software. It uses generic algorithm and considers 
full ligand conformational flexibility and partial protein flexibility. The binding site for DOR, 
in literature [9], was defined as residues within 10 Å radius of aspartic acid of third TM 
domain, which is involved in the most crucial interaction. In the case of DOR this is Asp 128. 
All scoring functions of GOLD were used. The conformations of the ligands with best scoring 
functions were selected and parameters of the scoring functions were use in order to find 
correlations between them and previously obtained in vitro results. The following three, very 
important parameters were obtained for all compounds from in vitro bioassay: IC50 – potency, 
KA – affinity and erel – efficacy. Their relevance was well-argumented by Pencheva et al., [8] 
and Milanov and Pencheva [9].   INT. J. BIOAUTOMATION, 2013, 17(1), 5-16 
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Table 2. Values of IC50, KA and erel obtained in mouse vas deferens by in vitro assay [8] 
  Ligand  IC50 (nM)  KA (nM)  erel 
1 DPDPE  6.18±1.17  180±35  30.2±10.0 
2 [Leu
5]-enk 11.45±2.06  54.9±13.1  5.8±1.0 
3 [Met
5]-enk 18.91±2.15  48.4±7.5  3.6±0.3 
4 [Cys(Bzl)
2, Leu
5]-enk 8.30±1.40 68.5±29.7  9.3±3.2 
5 [Cys(Bzl)
2, Met
5]-enk 9.53±1.20 23.8±3.0  3.5±0.3 
6 [Cys(O2NH2)
2, Leu
5]-enk 1.29±0.31  36.4±16.4  29.2±9.5 
7 [Cys(O2NH2)
2, Met
5]-enk 2.22±0.45  14.1±5.4  7.3±2.0 
8 [DCys(O2NH2)
2, Leu
5]-enk 11.40±2.01  73.4±12.7  7.4±1.9 
9 [DCys(O2NH2)
2, Met
5]-enk 75.96±11.67  463±161  7.1±1.8 
10 [HCys(O2NH2)
2, Leu
5]-enk 31.92±5.10  76.4±7.1  3.4±0.2 
11 [HCys(O2NH2)
2, Met
5]-enk 16.09±1.90  55.7±6.1  4.5±0.3 
 
 
Correlations 
In order to find relationship between sets of data derived from in vitro assay and docking 
results, we tried to predict it with the help of Pearson's correlation, using GraphPad Prism 3.0. 
 
 
Results and discussion 
Sequence alignment 
The final MSA for DOR is presented in Fig. 1. This result indicates that the sequences chosen 
are reasonably good to be used for homology modeling. The percentage of homologous 
residues in TM regions proved that these alignments are good (Table 3). It was found in 
MSA, that there was a sequence similarity greater than 50% in almost all TM regions. Thus, it 
could be expected that homology models built with this alignment would be more accurate. 
 
Homology modelling 
The 3D models with multiple alignments for DOR from respective templates, contain seven 
TM regions, as evident in all GPCRs. Homology models were generated with the focus to get 
suitable 3D models for docking and other in silico experiments in the absence of 
crystallographic structures.  
 
Evaluations of the 3D models were done for various levels of structural organization and 
basing on in vitro studies. We generate 30 models using MODELLER of Chimera. Six of 
them with best GA341 (more than 0.95) were chosen for further evaluation and were pointed 
as Model A-F. The results of stereochemical check of backbone with PROCHECK for these 
models are presented in Table 4. 
   INT. J. BIOAUTOMATION, 2013, 17(1), 5-16 
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Table 3. Percentage of residues identical or strongly similar  
with DOR sequence and different templates for each domain. 
Percentage of residues identical or strongly similar for each domain 
Sequences 
TM I  TM II  TM III  TM IV  TM V  TM VI  TM VII 
2y00 68 67  80  60  65  73 75 
2ycx 68 67  80  60  65  73 75 
2r4s 68 67  80  60  61  73 75 
3vg9  81  67  83  100  68  87  83 
2ks9 100 87 83 67  73  93 33 
4a4m 0 62  75  67  85  85 67 
 
 
 
 
Fig. 2 Ramachandran plot of Model D of δ-opioid receptor,  
obtained by PROCHECK. Plot for the best model is presented. 
 
 
 
Table 4. PROCHECK results for selected DOR models 
Model  Most favored  
regions, (%) 
Additionally 
allowed regions, (%) 
Generally allowed 
regions, (%) 
Disallowed 
regions, (%) 
A 93.8  5.5  0.3  0.3 
B 92.6  6.2  0.9  0.3 
C 93.2  5.8  0.3  0.6 
D 93.2  5.8  0.0  0.9 
E 91.1  7.1  1.5  0.3 
F 92.0  6.5  0.9  0.6   INT. J. BIOAUTOMATION, 2013, 17(1), 5-16 
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The results for the same Models A-F with the next tool, MolProbity score are shown in  
Table 5. 
 
Table 5. MolProbity score for selected DOR models 
Model  Residues in favored 
regions, (%) 
Residues in allowed 
regions, (%) 
A 96.8  99.5 
B 96.5  99.5 
C 96.2  99.2 
D 97.0  99.2 
E 94.3  99.2 
F 95.9  99.2 
 
 
Docking results 
An earlier study of Befort et al. [10] has shown that aspartic acid of TM III is important 
residue for ligand recognition. The binding site was defined as residues within 10 Å radius of 
Asp128 of the DOR. Docking was performed with all six models and 11 ligands. The results 
of docking studies of the ligands with the best model – Model B, are presented in Fig. 3, 
where the numbers correspond to the respective ligand form Table 1.  
 
 
 
Fig. 3 Binding of all 11 ligands with Model B of DOR 
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The best poses, including the interactions between target and ligands, obtained from docking 
with Model B of DOR, are presented in Table 6. 
 
In all cases ligands interact with receptor in the cavity around Asp128 with 10 Å in radius. 
These results suggest the reliability of the selected model of DOR. 
 
Correlations 
Correlations of molecular docking data and in vitro studies are performed with GraphPad 
Prism 3.0. All parameters form in vitro studies such as IC50, KA and erel are compared with the 
results from docking (fitness scoring function) in order to find correlation. It was found, that 
the parameter erel correlates with Fitness scoring function in five models. These data are 
presented in the Table 7. 
 
 
Table 6. Hydrogen bonds between ligands and receptor 
Number Ligand  Number  
of H-bonds
Residues, involved in H-bond 
formation 
1 DPDPE  7 
Gln105 (2H-bonds), Lys108, 
Pro205, Trp207, Asp293, and 
His301 
2 [Leu
5]-enk 1  Asp293 
3 [Met
5]-enk 5 
Gln105 (2H-bonds), Trp209 (2H-
bonds), Thr189 
4 [Cys(Bzl)
2, Leu
5]-enk  4  Gln105, Cys303 and His301 
5 [Cys(Bzl)
2, Met
5]-enk 2  Gln105  (2H-bonds) 
6 [Cys(O2NH2)
2, Leu
5]-enk 4 
Gln105, Leu302, His301, and 
Cys303 
7 [Cys(O2NH2)
2, Met
5]-enk  3  Gln105, Val297 and Cys303 
8 [DCys(O2NH2)
2, Leu
5]-enk 3  Gln105 (2H-bonds) and Ser206 
9 [DCys(O2NH2)
2, Met
5]-enk 2 Ser206  and  His301 
10 [HCys(O2NH2)
2, Leu
5]-enk 7 
Leu302 (2H-bonds), Cys302 
(2H-bonds), Gln105, Asp293, 
Val297 
11 [HCys(O2NH2)
2, Met
5]-enk 4 
Gln105, Asp293, His301, and 
Cys303 
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Table 7. Correlation between fitness scoring function from GOLD docking procedure  
and erel parameter of in vitro studies 
Model Pearson's  correlation,  r  p-value 
A -  0.6491  0.0307 
B -  0.7368  0.0097 
C -  0.6479  0.0311 
D -  0.6420  0.0332 
E -  0.7495  0.0079 
F -  0.5156  0.1045 
 
 
Best Pearson’s correlation was obtained for Model E of DOR, presented in Fig. 4.  
 
 
 
Fig. 4 Pearson’s correlation of erel and fitness of ligands  
with Model E (A) and Model B (B) of DOR 
 
 
The Model F can be excluded for further assessment, basing on comparative evaluation of all 
results obtained for DOR models. However, Model E with the best value of Pearson’s 
correlation is not satisfactory because according to of PROCHECK and MolProbity results 
the conformation of its 3D structure is inappropriate. So, the most acceptable model appears 
to be Model B. It shows good reliability in PROCHECK and MolProbity evaluation and 
reveals good correlation between in vitro results, concerning efficacy, and docking scoring 
function. 3D model of DOR – Model B is presented in Fig. 5. 
 
Conclusion 
New model of DOR was generated and evaluated by different approaches. This model has 
good GA341 value (0.99) from MODELLER, good values from PROCHECK (92.6% of most 
favored regions) and MolProbity (99.5% of favored regions). Scoring function correlates 
(Pearson’s correlation r = -0.7368, p-value = 0.0097) with erel  of a series of enkephalin 
analogues, calculated from in vitro experiments. So, this investigation  allows offering a 
reliable model of DOR. 
   INT. J. BIOAUTOMATION, 2013, 17(1), 5-16 
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Fig. 5 3D model of DOR – Model B, generated by MODELLER.  
Colors of the backbone based on the secondary structure information:  
α-helices are colored red, and coil is colored gray. 
 
 
Newly generated model of DOR receptor could be used further for in silico experiments and it 
will give possibility for faster and more correct design of selective and effective ligands for 
DOR. Moreover, it could be compared in further studies with recently published data for 
crystal structure of DOR [11].  
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